(NASDAQ: EVOK) Evoke Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 1,020.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.26%.
Evoke Pharma's earnings in 2025 is -$5,382,310.On average, 3 Wall Street analysts forecast EVOK's earnings for 2025 to be -$3,115,683, with the lowest EVOK earnings forecast at -$2,993,500, and the highest EVOK earnings forecast at -$3,207,321. On average, 3 Wall Street analysts forecast EVOK's earnings for 2026 to be $1,017,366, with the lowest EVOK earnings forecast at $977,469, and the highest EVOK earnings forecast at $1,047,288. 
In 2027, EVOK is forecast to generate $3,195,165 in earnings, with the lowest earnings forecast at $3,069,864 and the highest earnings forecast at $3,289,140.